KCM
UTHR icon

Kennedy Capital Management’s United Therapeutics UTHR Stock Holding History

Kennedy Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-22,796
Closed -$2.92M – 742
2018
Q3 		$2.92M Sell
22,796
-11
-0% -$1.36K 0.05% 536
2018
Q2 		$2.58M Buy
22,807
+2,186
+11% +$240K 0.05% 568
2018
Q1 		$2.32M Sell
20,621
-4,348
-17% -$552K 0.05% 579
2017
Q4 		$3.69M Sell
24,969
-2,782
-10% -$354K 0.07% 512
2017
Q3 		$3.25M Buy
+27,751
New +$3.54M 0.06% 548

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Kennedy Capital Management's UTHR Position: Q4 2018 in Review

Kennedy Capital Management sold out of United Therapeutics (UTHR) in Q4 2018, closing a stake of 22,796 shares — an estimated $2.92M sold.

Kennedy Capital Management first reported a position in UTHR in Q3 2017 and held it in 5 quarters. The position peaked at $3.69M in Q4 2017. 360 funds tracked by Wall St. Rank hold UTHR as of Q4 2018.

  • Kennedy Capital Management reported no remaining United Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Kennedy Capital Management sold 22,796 United Therapeutics shares in Q4 2018, an estimated $2.92M.
  • Kennedy Capital Management first reported a position in United Therapeutics in Q3 2017 and held it in 5 quarters.
  • Kennedy Capital Management's United Therapeutics position peaked at $3.69M in Q4 2017.
  • 360 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2018.

Based on Kennedy Capital Management's 13F filing for Q4 2018, filed 12 Feb 2019.